Skip to content

Study · Observational study · 2025

2 results

Genetic and physiological insights into satiation variability predict responses to obesity treatment.

Cifuentes L, Anazco D, O'Connor T, Hurtado MD, Ghusn W, Campos A, Fansa S, McRae A, Madhusudhan S, Kolkin E, Ryks M, Harmsen WS and 5 more

Show all authors

Ciotlos S, Abu Dayyeh BK, Hensrud DD, Camilleri M, Acosta A

Cell metabolism6 Jun 2025Cited by 19 (Europe PMC)

PMID40482646 (opens in a new tab)PMCIDPMC12236147 (opens in a new tab)DOI10.1016/j.cmet.2025.05.008 (opens in a new tab)PepBankPUB-40482646
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Satiation, the process that regulates meal size and termination, varies widely among adults with obesity. To better understand and leverage this variability, we assessed calories to satiation (CTS) through an ad libitum meal, combined with physiological and behavioral evaluations, including calorimetry, imaging, blood sampling, and gastric emptying tests. Although factors like baseline characteristics, body composition, and hormone levels partially explain CTS variability, they leave substantial variability unaccounted for. To address this gap, we developed a machine-learning-assisted genetic risk score (CTSGRS) to predict high CTS. In a randomized clinical trial, participants with high CTS or CTSGRS achieved greater weight loss with phentermine-topiramate over 52 weeks, whereas those with low CTS or CTSGRS responded better to liraglutide at 16 weeks in a separate trial. These findings highlight the potential of combining satiation measurements with genetic modeling to predict treatment outcomes and inform personalized strategies for obesity management.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with obesity, low measured calories to satiation was associated with a better liraglutide weight-loss response at 16 weeks; the comparator, signed coefficient and analyzed N were unstated.

    In plain wordsIn adults with obesity, low measured satiation calories were linked to a better liraglutide response at 16 weeks; the comparison was unspecified.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedWeight-loss response associated with low calories to satiation
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    whereas those with low CTS or CTSGRS responded better to liraglutide at 16 weeks in a separate trial.
    2 context sentences
    Summary · context
    Satiation, the process that regulates meal size and termination, varies widely among adults with obesity.
    Summary · context
    To better understand and leverage this variability, we assessed calories to satiation (CTS) through an ad libitum meal, combined with physiological and behavioral evaluations, including calorimetry, imaging, blood sampling, and gastric emptying tests.
  2. 02HumanObservational studyEfficacy outcome

    In adults with obesity, a low calories-to-satiation genetic risk score was associated with a better liraglutide weight-loss response at 16 weeks; the comparator, signed coefficient and analyzed N were unstated.

    In plain wordsIn adults with obesity, a low satiation genetic-risk score was linked to a better liraglutide response at 16 weeks; the comparison was unspecified.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedWeight-loss response associated with low calories-to-satiation genetic risk score
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    whereas those with low CTS or CTSGRS responded better to liraglutide at 16 weeks in a separate trial.
    2 context sentences
    Summary · context
    Satiation, the process that regulates meal size and termination, varies widely among adults with obesity.
    Summary · context
    To address this gap, we developed a machine-learning-assisted genetic risk score (CTSGRS) to predict high CTS.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.